Mesa Laboratories declared a quarterly dividend of $0.16 per share, payable on June 15, 2026.
Quiver AI Summary
Mesa Laboratories, Inc. has announced a quarterly dividend of $0.16 per share, set to be paid on June 15, 2026, to shareholders on record by May 29, 2026. The company is recognized as a leader in designing and manufacturing life science tools and quality control solutions in regulated sectors such as pharmaceuticals, healthcare, and medical devices. The press release also contains forward-looking statements regarding the company's future performance and various risks that could impact results. Mesa advises caution regarding these statements and emphasizes that actual outcomes may differ significantly from projections. For further details, stakeholders can refer to the company's annual and quarterly reports filed with the SEC.
Potential Positives
- The declaration of a regular quarterly dividend of $0.16 per share reflects the company's commitment to returning value to shareholders.
- The upcoming dividend payment date of June 15, 2026, indicates the company's positive cash flow and financial health.
- This announcement may enhance investor confidence and attract new investors interested in dividend-paying stocks.
- Mesa Laboratories, Inc. is positioned as a global leader in life science tools and quality control solutions, which underlines its market significance and stability.
Potential Negatives
- The declaration of a quarterly dividend may suggest lower than expected cash flow, raising concerns among investors about the company's financial health.
- The inclusion of forward-looking statements highlights risks and uncertainties that could negatively impact future performance, potentially undermining investor confidence.
FAQ
What is the recent dividend declared by Mesa Laboratories, Inc.?
Mesa Laboratories, Inc. announced a quarterly dividend of $0.16 per share, payable on June 15, 2026.
When will the dividend be paid to shareholders?
The dividend will be payable on June 15, 2026, to shareholders of record as of May 29, 2026.
What industries does Mesa Laboratories serve?
Mesa Laboratories serves the pharmaceutical, healthcare, and medical device industries by offering life science tools and quality control solutions.
Where can I find more information about Mesa Laboratories?
For more information about Mesa Laboratories, visit their official website at www.mesalabs.com.
What should investors know about forward-looking statements from Mesa?
Investors should note that forward-looking statements are subject to risks and uncertainties that might affect actual results.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MLAB Insider Trading Activity
$MLAB insiders have traded $MLAB stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MLAB stock by insiders over the last 6 months:
- SHIRAZ SHABANALI LADIWALA purchased 3,500 shares for an estimated $252,805
- R TONY TRIPENY purchased 1,315 shares for an estimated $99,940
- MARK CHRISTOPHER CAPONE purchased 1,301 shares for an estimated $99,331
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MLAB Revenue
$MLAB had revenues of $65.1M in Q3 2026. This is an increase of 3.64% from the same period in the prior year.
You can track MLAB financials on Quiver Quantitative's MLAB stock page.
$MLAB Hedge Fund Activity
We have seen 89 institutional investors add shares of $MLAB stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONESTOGA CAPITAL ADVISORS, LLC removed 426,457 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $33,476,874
- LONG PATH PARTNERS LP added 227,223 shares (+inf%) to their portfolio in Q4 2025, for an estimated $17,837,005
- SIMCOE CAPITAL MANAGEMENT, LLC removed 190,929 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $14,987,926
- GLENMEDE TRUST CO NA removed 146,544 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,503,704
- MILLENNIUM MANAGEMENT LLC removed 129,352 shares (-96.7%) from their portfolio in Q4 2025, for an estimated $10,154,132
- BOSTON PARTNERS added 99,019 shares (+86.6%) to their portfolio in Q4 2025, for an estimated $7,772,991
- SELECT EQUITY GROUP, L.P. added 79,720 shares (+62.9%) to their portfolio in Q4 2025, for an estimated $6,258,020
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LAKEWOOD, Colo., April 02, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026.
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2025, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.
CONTACT: John Sakys; CFO, Mesa Laboratories, Inc., +1-303-987-8000
For more information about the Company, please visit its website at www.mesalabs.com
